Onyx™ 液体栓塞 IDE 临床研究
PELE IDE 临床研究,外周 Onyx™ 液体栓塞安全性以及 Onyx™ LES 栓塞外周脉管系统动脉出血的有效性
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
研究概览
详细说明
This is a pivotal, prospective, multi-center, non-randomized, single arm study. This study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. In this study, peripheral vasculature is defined as outside of the brain and heart.
Approximately 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the US.
This study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. Reintervention visits will be captured through 30 days post-index procedure.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Liza Marie
- 电话号码:7072172314
- 邮箱:liza.marie@medtronic.com
研究联系人备份
- 姓名:Janki Shah
- 电话号码:7322662503
- 邮箱:janki.shah@medtronic.com
学习地点
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Mayo Clinic
-
接触:
- Debbie Ryan
- 电话号码:480-342-1208
- 邮箱:ryan.debra29@mayo.edu
-
首席研究员:
- Sadeer Alzubaidi, MD
-
接触:
- Yahaira Parker
-
-
California
-
Irvine、California、美国、92627
- 招聘中
- University of California, Irvine
-
接触:
- Nadine Jaoudeh, MD
- 邮箱:nadine@hs.uci.edu
-
接触:
- Kimberly Padilla
- 邮箱:kpadill6@hs.uci.edu
-
Los Angeles、California、美国、90095
- 招聘中
- University of California Los Angeles
-
接触:
- Renato Escobar
- 邮箱:raescobar@mednet.ucla.edu
-
首席研究员:
- Jessica Stewart, MD
-
Palo Alto、California、美国、94304
- 招聘中
- Stanford Medical Center
-
接触:
- Andrew Picel, MD
-
接触:
- Abigail Bond
- 邮箱:abond02@stanford.edu
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- UCHealth University of Colorado Hospital
-
接触:
- Alejandra Aguilar, MPH
- 邮箱:alejandra.aguilar@cuanschutz.edu
-
首席研究员:
- Eduardo Bent Robinson, MD
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 招聘中
- Yale New Haven
-
接触:
- Patricia Fugal
- 邮箱:patricia.fugal@yale.edu
-
接触:
- Angelo Marino, MD
- 邮箱:angelo.marino@yale.edu
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago
-
接触:
- Tiana Jackson
- 邮箱:tiana.jackson@bsd.uchicago.edu
-
首席研究员:
- Brian Funaki, MD
-
-
Iowa
-
Iowa City、Iowa、美国、52242
- 招聘中
- University of Iowa Hospitals and Clinics
-
首席研究员:
- Michael Hummel, MD
-
接触:
- Victoria Mendoza
- 邮箱:victoria-mendoza@uiowa.edu
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- 招聘中
- Masschusetts General Hospital
-
接触:
- Vincent Wu, MD
- 邮箱:vwu3@mgh.harvard.edu
-
接触:
- Justin Hill
- 邮箱:jhill43@mgh.harvard.edu
-
-
Nebraska
-
Omaha、Nebraska、美国、68124
- 招聘中
- CHI Health Creighton University Medical Center-Bergan-Mercy
-
接触:
- Janice Mitchel
- 电话号码:402-619-9402
- 邮箱:jan.mitchell@commonspirit.org
-
首席研究员:
- Patrick Harty
-
-
New Jersey
-
Newark、New Jersey、美国、07103
- 招聘中
- Rutgers New Jersey Medical School
-
首席研究员:
- Abhishek Kumar, MD
-
接触:
- Saharsh Patel
- 邮箱:ssp186@gsbs.rutgers.edu
-
-
New York
-
Albany、New York、美国、12208
- 招聘中
- Albany Medical Center
-
接触:
- Nancy Spencer, NP
- 邮箱:spencen@amc.edu
-
接触:
- Gary Siskin, MD
- 邮箱:sisking@amc.edu
-
New York、New York、美国、10029
- 招聘中
- The Mount Sinai
-
接触:
- Rajesh Patel, MD
- 邮箱:rajesh.patel@mountsinai.org
-
接触:
- Aaron Greenberg
- 邮箱:aaron.greenberg@mountsinai.org
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27599
- 招聘中
- University of North Carolina at Chapel Hill
-
首席研究员:
- Nima Kokabi, MD
-
接触:
- Adriana Delgado
- 邮箱:adriana_delgado@med.unc.edu
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 招聘中
- University Hospitals Cleveland Medical Center
-
接触:
- Lauren Hahn
- 邮箱:lauren.hahn@uhhospitals.org
-
首席研究员:
- Salim Abboud, MD
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University
-
接触:
- Mina Makary, MD
-
接触:
- Gage Spears
- 邮箱:gage.spears@osumc.edu
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15237
- 招聘中
- University of Pittsburgh Medical Center
-
首席研究员:
- Paula Novelli, MD
-
接触:
- Suzanne Burdin
- 邮箱:burdins@upmc.edu
-
-
Tennessee
-
Nashville、Tennessee、美国、37212
- 招聘中
- Vanderbilt University Medical Center
-
接触:
- Celia Nunez
- 电话号码:615-322-4559
- 邮箱:celia.m.nunez@vumc.org
-
首席研究员:
- Anthony Borgmann, MD
-
-
Texas
-
Dallas、Texas、美国、75235
- 招聘中
- Univ Of Texas Southwestern
-
首席研究员:
- Sanjeeva Kalva, MD
-
接触:
- Camille Harry
- 电话号码:214-648-8986
- 邮箱:camille.harry@utsouthwestern.edu
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas Health Science Center at Houston
-
接触:
- Praneeth Nadimpalli
- 邮箱:praneeth.v.nadimpalli@uth.tmc.edu
-
接触:
- Lauren McGuire, RN
- 邮箱:lauren.c.mcguire@uth.tmc.edu
-
首席研究员:
- Rodrick Zvavanjanja, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Patient is ≥ 22 years old.
-
Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
In this study, peripheral vasculature is defined as outside the brain and heart.
-
Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
-
Life expectancy of >30 days, in the opinion of the investigator at the time of enrollment.
-
Target treatment area is free from prior embolization treatment.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.
- Target vasculature unsuitable for the delivery of Onyx™ based upon physician assessment.
- More than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment with Onyx LES
Device; embolization with liquid embolic |
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Freedom from Arterial Hemorrhage
大体时间:Through 30 days post-index procedure
|
Freedom from arterial hemorrhage in all target location(s) after treatment with Onyx™ LES at the index procedure without re-embolization or any other intervention at the target location(s) due to persistent or recurrent hemorrhage through 30 days. Freedom from arterial hemorrhage where an arterial hemorrhage event is defined as a type 3 or greater BARC bleeding criteria as assessed by the Clinical Events Committee (CEC) through 30 days. |
Through 30 days post-index procedure
|
|
Freedom from System-related Major Adverse Events (MAE)
大体时间:Through 30 days post-index procedure
|
The primary safety endpoint is defined as freedom from system-related Major Adverse Events (MAE) through 30 days after the point of enrollment as assessed by the CEC. |
Through 30 days post-index procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Procedural Success
大体时间:At the completion of the index procedure
|
successful delivery and deployment of Onyx™ to the target location without non-target embolization or Onyx™ cast migration and the successful removal of the delivery system at the completion of the index procedure. |
At the completion of the index procedure
|
|
Technical Success
大体时间:At the completion of the index procedure
|
Technical Success is defined as absence of angiographic signs of bleeding after Onyx ™ embolization at each target location based on core lab assessment. |
At the completion of the index procedure
|
|
Reintervention
大体时间:Through 30 days post-index procedure
|
Reintervention is defined as the number of additional procedures needed to treat the target location(s) embolized with Onyx™ through 30 days following the index procedure. |
Through 30 days post-index procedure
|
|
Transfusions
大体时间:Through 30 days post-index procedure
|
Transfusions defined as the number of blood transfusions required post-index procedure through 30 days will use blood transfusions starting after the removal of the delivery system. The number of blood units used for each transfusion will also be collected. |
Through 30 days post-index procedure
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Ancillary Endpoint
大体时间:Through index procedure
|
Duration of the index procedure |
Through index procedure
|
|
Ancillary Endpoint
大体时间:Through 30 days post-index procedure
|
Length of hospitalization, post-index procedure |
Through 30 days post-index procedure
|
|
Ancillary Endpoint
大体时间:Through 30 days post-index procedure
|
Tabulate adjunctive use of other types of embolic agents to treat target locations at index procedure and reinterventions |
Through 30 days post-index procedure
|
合作者和调查者
调查人员
- 首席研究员:Osman Ahmed, MD、University of Chicago
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.